Watch CBSN Live

FDA Gives Allergan a Stats Lesson in Bold Type

Could the FDA be signalling a more aggressive regulatory stance under the Obama administration through its use of dramatic adverbs and bold type? That's one way to read a warning letter the FDA sent to Allergan regarding a journal ad for its Aczone acne product.

The letter is also worth reading as a guide for laypersons to the way statistics can be manipulated in ads:

The journal ad claims that "[ACZONE] Works fast 24% reduction in inflammatory lesions at 2 weeks" (emphasis in original). This claim is a complete misrepresentation of the results of the Draelos study. [J Am Acad Dermatol. 2007.]
That bold type was in the original FDA letter. On the manipulation of statistics, the FDA said:
... at 2 weeks, the mean percent change in inflammatory lesion count in patients on dapsone gel was 24% and in patients on placebo was 22%, demonstrating an actual effect of 2%, which was not even nominally statistically significant (p=0.052).
Wait for the adverb, also in bold:

... the journal ad grossly overstates the efficacy of the drug by presenting only the most favorable result for ACZONE and ignoring the placebo response ...

Got that?

View CBS News In
CBS News App Open
Chrome Safari Continue